Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BB Biotech ( (CH:BION) ) just unveiled an update.
BB Biotech AG expects to report an unaudited profit of around CHF 578 million for the 2025 financial year, a sharp increase from CHF 76 million a year earlier, reflecting strong share price performance among the biotech companies in its portfolio. The company plans to publish detailed portfolio information and its full annual report on 20 February 2026, with the robust result underlining its positioning as a major specialist investor in the biotech sector and signaling significant value creation for shareholders over the past year.
The most recent analyst rating on (CH:BION) stock is a Buy with a CHF56.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.
More about BB Biotech
BB Biotech AG is a Swiss-based investment company listed on the Swiss and German stock exchanges, focusing on equity stakes in innovative drug development firms primarily in the US and Western Europe. Positioned as one of the leading investors in the biotechnology sector, its board sets the investment strategy while portfolio decisions are executed by Bellevue Asset Management’s specialist team, leveraging in-depth research on biotech companies.
Average Trading Volume: 86,468
Technical Sentiment Signal: Buy
Current Market Cap: CHF2.58B
See more insights into BION stock on TipRanks’ Stock Analysis page.